Numerous attempts have been made to block the IGF system for treatment of tumours (reviewed by Surmacz, 2003) but most of the methods had different problems as lack of specificity, difficulty of drug delivery, etc. One of the most promising approach is to use specific small molecules that inhibit IGF-IR tyrosine kinase (LeRoith and Helman, 2004). The gene discussed is IGF1; the disease is neoplasm.